Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Factor D inhibitor (oral complement inhibitor, adjunctive)

Danicopan

Brand names: Voydeya

Danicopan is an oral complement factor D inhibitor used as add-on therapy in paroxysmal nocturnal haemoglobinuria (PNH) for patients with clinically significant extravascular haemolysis on a C5 inhibitor.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits factor D, a protease of the alternative complement pathway, thereby reducing the C3-mediated opsonisation that drives extravascular haemolysis when terminal (C5) inhibition is already in place.

Prescribing in practice

  • As a complement inhibitor it increases the risk of infection with encapsulated organisms, so meningococcal and other appropriate vaccination must be ensured before starting.
  • It is used as an add-on to an existing C5 inhibitor, not as monotherapy, and the C5 inhibitor should be continued.
  • Hepatic enzymes may rise; baseline and periodic liver function assessment is appropriate.

Monitoring

Monitor haemoglobin and markers of haemolysis, liver function, and for any sign of serious infection.

Counselling the patient

  • Continue your existing complement medicine; this is added on top of it, not a replacement.
  • Carry your patient safety card and seek urgent care for fever, severe headache or neck stiffness.
  • Keep meningococcal and other recommended vaccinations up to date.

Evidence & guidelines

The ALPHA trial showed improvement in haemoglobin with danicopan added to C5 inhibition for extravascular haemolysis in PNH; consult current prescribing references.

Reference: NICE TA evaluation; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways